Nanyang Biologics
PrivateLast Round
M&A
Oct 2, 2025
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nanyang Biologics is a biotechnology company that provides an AI-driven drug discovery and nature-derived therapeutic platform for longevity and disease treatment.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Platform-as-a-Service
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanyang Biologics Comparables
Compare Nanyang Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enveda Biosciences | 81% | |
| Kapoose Creek Bio | 81% | |
| Brightseed | 80% |
Nanyang Biologics Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
Nanyang Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mercatus Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 2, 2026
Grew 28% QoQ, from 29 to 37 employees.
- Aug 1, 2026
Grew 40% QoQ, from 25 to 35 employees.
Recent news
Latest coverage and updates
- has_valuationOct 14, 2026
The proposed business combination values Nanyang Biologics Pte. Ltd. at between $1.5B and US$2.2 billion after RF Acquisition Corp II shareholders approve the transaction in Aug '26.
- launchesAug 11, 2026
Nanyang Biologics Pte. Ltd. designs the Vecura(TM) AI platform for AI-driven discovery of novel bioactive candidates and underexplored mechanisms.
Nanyang Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nanyang Biologics's valuation, stock price, and market status.
Is Nanyang Biologics a public or private company?
Nanyang Biologics is a private company.
What is the current stock price of Nanyang Biologics?
Nanyang Biologics is a private company, so its shares have no public market price. Caplight tracks Nanyang Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nanyang Biologics worth (valuation)?
Valuation information for Nanyang Biologics is not publicly available.
Can I buy Nanyang Biologics stock?
Nanyang Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nanyang Biologics's last funding round?
Nanyang Biologics's most recent funding round was M&A on October 2, 2025.
Who are the main investors in Nanyang Biologics?
Key investors in Nanyang Biologics include Mercatus Capital.
Will Nanyang Biologics IPO soon?
No public IPO plans have been announced for Nanyang Biologics.
How can I track Nanyang Biologics secondary market activity?
Caplight tracks bids, offers, and trades in Nanyang Biologics's shares on secondary markets.